Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegvisomant - Pfizer

Next Previous
X
Search
Drug Profile

Pegvisomant - Pfizer

Alternative Names: B2036-PEG; Somavert; Trovert

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech; Omeris
  • Developer Pfizer
  • Class Anterior pituitary hormones; Recombinant proteins
  • Mechanism of Action Somatotropin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acromegaly
  • Discontinued Cancer; Diabetic retinopathy

Most Recent Events

  • 13 Nov 2017 The Scottish Medicines Consortium accepts pegvisomant for routine use by NHS Scotland for the treatment of Acromegaly
  • 14 Jul 2017 EMA approves pegvisomant 25mg and 30mg for Acromegaly in European Union (SC) before July 2017
  • 31 Oct 2013 Pfizer completes a phase I trial to asses the pharmacokinetic comparability of pegvisomant doses in healthy volunteers in Belgium (NCT01893866)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top